rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Ivana Magovcevic-Liebisch

Director

Company insider

Files Form 4 as: Director, Quanterix; Director, Acrivon Therapeutics; President and CEO, Vigil Neuroscience; Director, Spyre Therapeutics; Director, Absci; Director, Applied Genetic Technologies; EVP; Chief Operating Officer, Dyax.

Every Form 4 they filed

In numbers

Trades disclosed
137
Buys
8
Sells
6
Bought
$98K
Sold
$980K
Companies
7
Companies where not an officer
5
First trade
3 Jul 2006
Last trade
2 Oct 2026
Last filed
2 Oct 2026

Companies traded

Where they are an officer
Vigil NeuroscienceDirector, Officer · last 5 Aug 20256 buys · 0 sells
DyaxDirector, Officer · last 29 Mar 20131 buy · 6 sells
Everywhere else they filed: board seats, 10% stakes, other companies
QTRX QuanterixDirector · Life-science tools · last 2 Oct 20260 buys · 0 sells
ACRV Acrivon TherapeuticsDirector · Biotechnology · last 17 Jun 20260 buys · 0 sells
SYRE Spyre TherapeuticsDirector · Biotechnology · last 22 Jun 20230 buys · 0 sells
ABSI AbsciDirector · Life-science tools · last 8 Jun 20220 buys · 0 sells
Applied Genetic TechnologiesDirector · last 30 Nov 20211 buy · 0 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
03Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
2 Oct 2026filed 2 Oct 2026QTRX QuanterixLife-science toolsSEC FORM 4 Code M—4,224filing
2 Oct 2026filed 2 Oct 2026QTRX Quanterixoption or derivative · Life-science toolsSEC FORM 4 Code M—4,224 at $0.00filing
17 Jun 2026filed 22 Jun 2026ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,275 at $0.00filing
17 Jun 2026filed 22 Jun 2026ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,275 at $0.00filing
18 May 2026filed 20 May 2026ACRV Acrivon TherapeuticsBiotechnologySEC FORM 4 Code A—9,366 at $0.00filing
18 May 2026filed 20 May 2026ACRV Acrivon TherapeuticsBiotechnologySEC FORM 4 Code A—9,366 at $0.00filing
2 Jan 2026filed 15 Jan 2026QTRX QuanterixLife-science toolsSEC FORM 4 Code A—23,372 at $0.00filing
2 Jan 2026filed 15 Jan 2026QTRX QuanterixLife-science toolsSEC FORM 4 Code A—23,372 at $0.00filing
5 Aug 2025filed 5 Aug 2025Vigil Neuroscienceoption or derivativeSEC FORM 4 Code D—369,351filing
5 Aug 2025filed 5 Aug 2025Vigil Neuroscienceoption or derivativeSEC FORM 4 Code D—210,629filing
5 Aug 2025filed 5 Aug 2025Vigil Neuroscienceoption or derivativeSEC FORM 4 Code D—405,494filing
5 Aug 2025filed 5 Aug 2025Vigil Neuroscienceoption or derivativeSEC FORM 4 Code D—43,271filing
5 Aug 2025filed 5 Aug 2025Vigil Neuroscienceoption or derivativeSEC FORM 4 Code D—282,000filing
5 Aug 2025filed 5 Aug 2025Vigil Neuroscienceoption or derivativeSEC FORM 4 Code D—370,000filing
5 Aug 2025filed 5 Aug 2025Vigil Neuroscienceoption or derivativeSEC FORM 4 Code D—463,000filing
5 Aug 2025filed 5 Aug 2025Vigil Neuroscienceoption or derivativeSEC FORM 4 Code D—485,000filing
5 Aug 2025filed 5 Aug 2025Vigil NeuroscienceSEC FORM 4 Code D—222,687filing
13 Jun 2025filed 17 Jun 2025ACRV Acrivon Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—20,275 at $0.00filing
3 Mar 2025filed 4 Mar 2025Vigil Neuroscienceoption or derivativeSEC FORM 4 Code A—485,000 at $0.00filing
2 Jan 2025filed 6 Jan 2025QTRX Quanterixoption or derivative · Life-science toolsSEC FORM 4 Code A—15,821 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed14

Buys in green, sells in red, by the company’s sector.

Related people

Nobody else traded the same names lately.